Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial.

S, Shoham; EM, Bloch; A, Casadevall; D, Hanley; B, Lau; K, Gebo; E, Cachay; SG, Kassaye; JH, Paxton; J, Gerber; AC, Levine; A, Naeim; J, Currier; B, Patel; ES, Allen; S, Anjan; L, Appel; S, Baksh; PW, Blair; A, Bowen; P, Broderick; CA, Caputo; V, Cluzet; ME, Cordisco; D, Cruser; S, Ehrhardt; D, Forthal; Y, Fukuta; AL, Gawad; T, Gniadek; J, Hammel; MA, Huaman; DA, Jabs; A, Jedlicka; N, Karlen; S, Klein; O, Laeyendecker; K, Lane; N, McBee; B, Meisenberg; C, Merlo; G, Mosnaim; HS, Park; A, Pekosz; J, Petrini; W, Rausch; DM, Shade; JR, Shapiro; JR, Singleton; C, Sutcliffe; DL, Thomas; A, Yarava; M, Zand; JM, Zenilman; AAR, Tobian; DJ, Sullivan

doi:10.1093/cid/ciac372

Public

Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial.

Shared by NobleBlocks on Feb 1, 2023 • 12:00 AM UTC

Authors:

Shoham S

Bloch EM

Casadevall A

Abstract

Background The efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. CCP might prevent infection when administered before symptoms or laboratory evidence of infection.Methods This dou...

Subject

Transfusion

Convalescent Plasma

Post-exposure-prophylaxis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!